By Professor Jerry Richard Greenfield

Conference Presentations

Lin J; Pearson S; Greenfield J; Park KH; Havard A; Brieger D; Day R; Falster M; de Oliveira Costa J, 2023, 'Trends in the use of Cardiometabolic Medicines in Australia (2014-2022): Sodium-glucose Co-transporter 2 Inhibitors and Glucagon-like Peptide-1 Analogues', presented at Australian Diabetes Congress 2023

Lin J; Pearson S; Greenfield J; Park KH; Havard A; Brieger D; Day R; Falster M, 2023, 'Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 analogues (GLP-1a) for cardiovascular risk in Australia (2014-2022)', presented at 39th International Conference on Pharmacoepidemiology & Therapeutic Risk Management 2023

Chowdhury G; Smith F; MacDonald P; Carland J; Stocker S; Kumar S; Greenfield J; Williams K; Graham G; Day R, 2017, 'The safety and pharmacokinetics of metformin in heart failure', presented at APSA-ASCEPT, Brisbane, Australia, 05 December 2017 - 08 December 2017

Smith F; Furlong T; Greenfield J; Stocker S; Carland J; Graham G; Williams K; Day R, 2017, 'The Safety of Metformin in Haemodiafiltration', presented at APSA-ASCEPT, Brisbane, Australia, 05 December 2017 - 08 December 2017

Smith F; Kumar S; Furlong T; Gangaram S; Greenfield J; Stocker S; Carland J; Graham G; Williams K; Day R, 2016, 'Extraction of Metformin During Haemodiafiltration', presented at ASCEPT-MPGPCR, Melbourne, 27 November 2016 - 30 November 2016

Greenfield JR; Samaras K; Campbell LV, 2013, 'Sugar-sweetened beverages, genetic risk, and obesity [1]', http://dx.doi.org/10.1056/NEJMc1213563

Back to profile page